SCHEMBL8302189

SCHEMBL8302189

CC(C)(C)OC(=O)CN(c1ccc(Br)cc1)S(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 3/20 0.44
MMP2 P08253 3/20 0.44
MMP9 P14780 3/20 0.44
RAB9A P51151 1/20 0.44
GAA P10253 1/20 0.42
PTPN1 P18031 2/20 0.42
PTPN6 P29350 1/20 0.42
PTPN11 Q06124 1/20 0.42
MAPK1 P28482 1/20 0.42
PER2 O15055 1/20 0.41
CRY1 Q16526 1/20 0.41
CRY2 Q49AN0 1/20 0.41
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14805378 0.83 SMN1; SMN2 (0.43) SMN1; SMN2LMNAALDH1A1MMP2MMP9
SCHEMBL24279552 0.83 MAPT (0.50) SMN1; SMN2LMNAALDH1A1MMP2MMP9
SCHEMBL1409649 0.79 SMN1; SMN2 (0.63) SMN1; SMN2LMNAALDH1A1MMP2MMP9
SCHEMBL4935409 0.77 ALDH1A1 (0.48) SMN1; SMN2LMNAALDH1A1MMP2MMP9
SCHEMBL2378054 0.76 SMN1; SMN2 (0.39) SMN1; SMN2LMNAALDH1A1MMP2MMP9
SCHEMBL31518476 0.71 ALDH1A1 (0.47) SMN1; SMN2LMNAALDH1A1MAPK1MEN1
SCHEMBL18346856 0.71 PER2 (0.47) SMN1; SMN2LMNAALDH1A1MMP2MMP9
SCHEMBL10000463 0.70 NCEH1 (0.44) SMN1; SMN2LMNAALDH1A1MAPK1MAPT
SCHEMBL2194247 0.70 SMN1; SMN2 (0.49) SMN1; SMN2LMNAALDH1A1MMP2MMP9
SCHEMBL3379013 0.70 ALDH1A1 (0.56) SMN1; SMN2LMNAALDH1A1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227858-A1 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED 2008-09-18 US disclosed
US-20080227858-A1 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED 2008-09-18 US disclosed
US-7375248-B2 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED (GB) 2008-05-20 US disclosed
US-7375248-B2 Inhibitors of matrix metalloproteinase GLAXO GROUP LIMITED (GB) 2008-05-20 US disclosed
WO-2004113279-A1 INHIBITORS OF MATRIX METALLOPROTEINASE GLAXO GROUP LIMITED (GB) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227858-A1 Inhibitors of matrix metalloproteinase MMP9, MMP13, MMP2 SMN1; SMN2 3365/4885LMNA 3942/4885ALDH1A1 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.